Ignite Creation Date:
2024-05-06 @ 3:57 PM
Last Modification Date:
2024-10-26 @ 2:00 PM
Study NCT ID:
NCT04811443
Status:
UNKNOWN
Last Update Posted:
2021-03-23
First Post:
2021-03-19
Brief Title:
DEFENDOR A Multicenter Prospective Observational Post-registration stuDy of Extimia INN empEgfilrastim to Evaluate Efficacy and saFEty in patieNts With soliD tumORs
Sponsor:
Biocad
Organization:
Biocad
Study Overview
Official Title:
DEFENDOR A Multicenter Prospective Observational Post-registration stuDy of Extimia INN empEgfilrastim to Evaluate Efficacy and saFEty in patieNts With soliD tumORs
Status:
UNKNOWN
Status Verified Date:
2021-03
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
DEFENDOR
Brief Summary:
This study was designed to evaluate the efficacy and safety of Extimia INN - empegfilgrastim in reducing the frequency duration of neutropenia the incidence of febrile neutropenia and infections caused by febrile neutropenia in patients with solid tumours receiving myelosuppressive therapy
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None